Herpesviruses, and the majority of the 1516647 human population will be exposed to CMV with a prevalence of more than 50 [1]. HCMV has the ability to establish a latent infection in the host after recovery from acute infection, allowing for a lifelong persistence of the virus in the host along with the risk for viral reactivation into the replicating state, HCMV viremia and disease at later time points [2] 3]. Clinically, severe HCMV disease is rarely seen in the MedChemExpress PD-1/PD-L1 inhibitor 1 healthy individual, but HCMV still poses a significant risk for morbidity and mortality in the immunecompromised host [4]. Allogeneic hematopoietic cell transplantation (HCT) is a 
potentially curative treatment option for a variety of hematological malignancies, immunodeficiencies and metabolic storage diseases.Improvements in immunosuppressive therapy, anti-infectious prophylaxis, infection management and better care during long term follow-up have significantly improved HCT outcome [5] 6]. Nevertheless, HCMV remains a significant cause of morbidity and mortality after allogeneic 
HCT [7]. CMV pneumonitis, colitis and hepatitis are potentially get Fexinidazole lethal [8], but have significantly decreased in their incidence since strategies to monitor for CMV reactivation following transplant and preemptive therapy have been employed as standard clinical practice [9]. A reciprocal relationship between viral replication and the development of acute graft versus host disease (GVHD) has been recently reported by Cantoni et al., [10], when GVHD and related immunosuppressive therapy increased the risk of HCMV replication, and when risk for acute GVHD development was augmented during HCMV replication. However, the same was not observed byCMV and GVHDWang et al., [11], and respective prospective clinical and experimental studies are still pending. Over the last decade, murine CMV (MCMV) has been well characterized as sharing strong similarities to HCMV [12] 13]. ?Following MCMV infection of naive mice, latency is established in various organs after different time points (spleen: 1? months; lungs: 3? months; salivary glands: 5? months) [14]. The cellular mechanism underlying MCMV viral reactivation is still not completely understood [15]. Previous studies suggested that reactivation is initiated by transcriptional activation of MCMV immediate-early (IE) genes, as they are the first to be detected during reactivation [16]. Using a murine HCT model, in which GVHD develops across minor histocompatibility antigen (mHag) mismatches, we now tested, whether severity of GVHD and HCT outcome are altered in latently MCMV infected recipients. Overall survival was decreased in allogeneic recipients, and MCMV reactivation determined by the expression of IE1 [17] occurred after HCT in the absence of medical immunosuppression and was linked to increased GVHD target organ injury.sections from individual mice were coded without reference to mouse type and independently examined by a pathologist (E.H.) to establish an index of GVHD injury. Lung tissue was evaluated for the presence of periluminal infiltrates (around airways and vessels) or parenchymal pneumonitis (involving the alveoli or interstitial space), using a modified semi-quantitative scoring system that incorporates both the severity (score 0?) and extent (percentage of lung space involvement) of disease [18]. Histopathologic changes of the liver were assessed in a semi-quantitative manner by analyzing 9 features that were graded from 0 (normal), 0.5 (focal and rare).Herpesviruses, and the majority of the 1516647 human population will be exposed to CMV with a prevalence of more than 50 [1]. HCMV has the ability to establish a latent infection in the host after recovery from acute infection, allowing for a lifelong persistence of the virus in the host along with the risk for viral reactivation into the replicating state, HCMV viremia and disease at later time points [2] 3]. Clinically, severe HCMV disease is rarely seen in the healthy individual, but HCMV still poses a significant risk for morbidity and mortality in the immunecompromised host [4]. Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment option for a variety of hematological malignancies, immunodeficiencies and metabolic storage diseases.Improvements in immunosuppressive therapy, anti-infectious prophylaxis, infection management and better care during long term follow-up have significantly improved HCT outcome [5] 6]. Nevertheless, HCMV remains a significant cause of morbidity and mortality after allogeneic HCT [7]. CMV pneumonitis, colitis and hepatitis are potentially lethal [8], but have significantly decreased in their incidence since strategies to monitor for CMV reactivation following transplant and preemptive therapy have been employed as standard clinical practice [9]. A reciprocal relationship between viral replication and the development of acute graft versus host disease (GVHD) has been recently reported by Cantoni et al., [10], when GVHD and related immunosuppressive therapy increased the risk of HCMV replication, and when risk for acute GVHD development was augmented during HCMV replication. However, the same was not observed byCMV and GVHDWang et al., [11], and respective prospective clinical and experimental studies are still pending. Over the last decade, murine CMV (MCMV) has been well characterized as sharing strong similarities to HCMV [12] 13]. ?Following MCMV infection of naive mice, latency is established in various organs after different time points (spleen: 1? months; lungs: 3? months; salivary glands: 5? months) [14]. The cellular mechanism underlying MCMV viral reactivation is still not completely understood [15]. Previous studies suggested that reactivation is initiated by transcriptional activation of MCMV immediate-early (IE) genes, as they are the first to be detected during reactivation [16]. Using a murine HCT model, in which GVHD develops across minor histocompatibility antigen (mHag) mismatches, we now tested, whether severity of GVHD and HCT outcome are altered in latently MCMV infected recipients. Overall survival was decreased in allogeneic recipients, and MCMV reactivation determined by the expression of IE1 [17] occurred after HCT in the absence of medical immunosuppression and was linked to increased GVHD target organ injury.sections from individual mice were coded without reference to mouse type and independently examined by a pathologist (E.H.) to establish an index of GVHD injury. Lung tissue was evaluated for the presence of periluminal infiltrates (around airways and vessels) or parenchymal pneumonitis (involving the alveoli or interstitial space), using a modified semi-quantitative scoring system that incorporates both the severity (score 0?) and extent (percentage of lung space involvement) of disease [18]. Histopathologic changes of the liver were assessed in a semi-quantitative manner by analyzing 9 features that were graded from 0 (normal), 0.5 (focal and rare).
